(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 28.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Tg Therapeutics's revenue in 2024 is $289,334,000.On average, 4 Wall Street analysts forecast TGTX's revenue for 2024 to be $45,659,713,100, with the lowest TGTX revenue forecast at $45,002,905,584, and the highest TGTX revenue forecast at $46,562,243,899. On average, 4 Wall Street analysts forecast TGTX's revenue for 2025 to be $68,423,888,899, with the lowest TGTX revenue forecast at $45,746,257,149, and the highest TGTX revenue forecast at $79,033,262,073.
In 2026, TGTX is forecast to generate $95,606,756,581 in revenue, with the lowest revenue forecast at $56,318,540,017 and the highest revenue forecast at $116,278,111,818.